Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 13,144 shares, a drop of 52.5% from the August 31st total of 27,645 shares. Based on an average daily trading volume, of 422,623 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.
Oncotelic Therapeutics Price Performance
Shares of OTCMKTS:OTLC traded down $0.00 during trading on Tuesday, hitting $0.02. 428,267 shares of the stock were exchanged, compared to its average volume of 283,978. The company has a market cap of $10.73 million, a PE ratio of 0.04 and a beta of -0.24. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $0.03 and a two-hundred day moving average price of $0.04. Oncotelic Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.11.
Oncotelic Therapeutics Company Profile
Oncotelic Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression.
Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors.
See Also
- Five stocks we like better than Oncotelic Therapeutics
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
